Acro Biomedical Co., Ltd.
ACBM· OTC
ACBMAcro Biomedical Co., Ltd.
Filed Jul 21, 2023 · 10-K · 202 days after period end · 0001640334-23-001347
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Revenue | $360.00K | $598.00K | $0.00 | $193.54K |
| Net Income | -$3.93M | -$3.85M | -$61.77K | -$75.87K |
| EPS Diluted | — | — |
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
| — |
| $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Jul 21, 2023 · 202 d after period end
